Hannah Glover on Muck Rack

Hannah Glover

Verified
New York
As seen in: Financial Times, Nature, MDPI, Science Magazine, Hull Daily Mail, Lexology, Mondaq, Independent Voter News, Financial Advisor IQ, Ignites, Agenda and
Covering the mutual fund industry.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hannah

Contact Hannah, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Hannah Glover’s Biography

Read Full Bio →

Hannah Glover is Managing Editor of Ignites. She joined Money-Media in 2007 as a reporter on Ignites, and later was managing editor of sister-publication GatekeeperIQ. Before covering the mutual fund industry, she reported for the Record Journal in Meriden, Conn. She is a graduate of Columbia University's Graduate School of Journalism and Boston College.

Articles

An integrated experimental and computational pipeline for crystallographic fragment screening of membrane protein in the lipid cubic phase

|
By Chia-Ying Huang, Robert K. Y. Cheng, Alexander Metz, Denis Bucher, Fabio Andrés, Hannah Glover Verified, Christoph P Sager, meitian Wang, Michel O. Steinmetz, Michael J. Hennig, May E. Sharpe, Arianna Bacchin
| Nature Verified
Abstract X-ray crystallographic fragment screening is a powerful strategy in modern drug discovery, enabling the identification of small-molecule starting points for rational hit-to-lead optimization.
Open in Who Shared Issue with article?

A fat-fueled fatality - Nature Chemical Biology

|
By Hannah Glover Verified
| Nature Verified
Targeting non-apoptotic cell death pathways is an attractive approach for treating apoptosis-resistant cancers. Tegavivint, a drug candidate undergoing clinical trials in different cancers, has been found to trigger a unique cell death pathway that acts via the synthesis of the saturated long-chain fatty acid palmitate.
Open in Who Shared Issue with article?

Kinetic Basis for the Design of Azobenzene-Based Photoswitchable A2a Adenosine Receptor Ligands

|
By Torben Saßmannshausen, Hannah Glover Verified, Matilde Cardoso Trabuco, Werner Neidhart
| dx.doi.org
Open in Who Shared Issue with article?
See all 17 licensed articles (19 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified